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The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases 
important for mitosis. Their activity and protein expression are cell cycle regulated, peak-
ing during mitosis to orchestrate important mitotic processes including centrosome mat-
uration, chromosome alignment, chromosome segregation, and cytokinesis. In humans, 
the Aurora kinase family consists of three members; Aurora-A, Aurora-B, and Aurora-C, 
which each share a conserved C-terminal catalytic domain but differ in their sub-cellular 
localization, substrate specificity, and function during mitosis. In addition, Aurora-A and 
Aurora-B have been found to be overexpressed in a wide variety of human tumors. 
These observations led to a number of programs among academic and pharmaceutical 
organizations to discovering small molecule Aurora kinase inhibitors as anti-cancer 
drugs. This review will summarize the known Aurora kinase inhibitors currently in the 
clinic, and discuss the current and future directions.
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iNTRODUCTiON
The Aurora kinases are a family of highly conserved serine/threonine kinases that are important 
for faithful transition through mitosis (1–3). The gene for Aurora-A, maps to chromosome region 
20q13.2, a region that has been found amplified in different human cancers. Aurora-A plays an 
important role in centrosome maturation, spindle assembly, meiotic maturation, and metaphase I 
spindle orientation [Figure 1 (2)]. Aurora-A function is regulated by degradation, phosphorylation, 
and dephosphorylation, with its kinase activity dependent upon phosphorylation of threonine 288 
(Thr288) in the activation loop (2). Selective inhibition of Aurora-A results in inhibition of autophos-
phorylation of Aurora-A at Thr288, monopolar spindles, and G2-M arrest (4, 5). The Aurora-B gene 
maps to chromosome region 17p13.1 (1, 6) and this kinase forms part of the chromosomal passenger 
complex (CPC) with three non-enzymatic subunits: inner centromere protein (INCENP), Survivin, 
and Borealin [Figure 1 (7)]. The highly dynamic CPC is critical for chromosome condensation, 
chromosome orientation on the mitotic spindle, through correcting chromosome-microtubule 
attachment errors, and the spindle-assembly checkpoint (SAC), as well as the final stages of cytokine-
sis (8–11). Aurora-C expression has been reported in testis, thyroid, and placenta and in meiotically 
dividing gametes (2, 12–15). Recently, it was demonstrated that overexpression of Aurora-C induces 
abnormal cell division resulting in centrosome amplification and multinucleation in cells. NIH3T3 
mouse fibroblasts overexpressing Aurora-C induced tumor formation in nude mice, demonstrating 
its oncogenic activity (16).
Aurora-A was first described in human cancer cell lines but has subsequently been found to be 
overexpressed in a broad range of human tumors, including primary colorectal carcinoma, gliomas, 
FiGURe 1 | Aurora-A and Aurora-B localization. Aurora-A (yellow) localizes at the centrosome during interphase and at the mitotic poles and the adjacent 
spindle microtubules during mitosis. Aurora-B (green) localizes at the chromosomes in prophase, the centromere in prometaphase and metaphase, and the central 
mitotic spindle in anaphase.
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breast, ovarian, and pancreatic cancers (1, 17–20). Aurora-B is 
also overexpressed in human tumors such as gliomas, thyroid 
carcinoma, seminoma, and colon cancer (21–23).
The overexpression of the Aurora kinases and their association 
with genetic instability and aneuploidy in tumors suggests that a 
wide range of cancers could respond therapeutically to inhibitors 
of the Aurora kinases (24). Over the past decade, many phar-
maceutical companies and academic institutions have reported 
the development of Aurora kinase inhibitors. Both Aurora-A 
and Aurora-B inhibitors induce cell death. However, they induce 
apoptosis through distinct mechanisms Figures  2A,B (25). 
Aurora-A inhibition induces defects in mitotic spindle assembly, 
which causes a transient spindle checkpoint-dependent mitotic 
arrest. This cell cycle arrest is not maintained, and subsequently, 
Aurora-A inhibited cells exit from mitosis leading to apoptosis, 
either by induction of a G1 arrest, followed by apoptosis, or by 
a p53-independent mechanism (25). In contrast, inhibition of 
Aurora-B also interferes with normal chromosome alignment 
during mitosis and overrides the mitotic spindle checkpoint 
causing polyploidy, failure of cytokinesis and endoreduplication 
followed by cell death at time more than 48 h (4, 5, 25). In a com-
pletely different direction, mechanistic studies have shown that 
Aurora-A inhibition also leads to MYCN degradation. The MYC 
family member MYCN, which is associated with amplification in 
the childhood tumor neuroblastoma, is stabilized by Aurora-A in 
a kinase-independent fashion, but involves a direct protein–pro-
tein interaction (26, 27). In this interaction, Aurora-A functions 
to sequester MYCN away from ubiquitin-mediated proteolytic 
degradation.
In this review, we will first present inhibitors of Aurora kinase 
family that have been recently assessed in clinical studies, with 
a focus on hematologic malignancies. Subsequently, we will 
discuss in more detail the areas in which inhibitors of Aurora 
kinases have shown greater promise, and we will highlight recent 
advances in the understanding of Aurora kinases biology that 
could be exploited with small-molecule modulators, bringing 
greater benefit to patients.
iNHiBiTORS OF AURORA KiNASeS iN 
CLiNiCAL TRiALS
Barasertib (AZD1152)
Barasertib (AZD1152, Table 1) is a phosphate-based prodrug that 
is rapidly converted into barasertib-hQPA (Table 1) in vivo (28, 
29). Barasertib-hQPA selectively inhibits the Aurora-B kinase 
(Aurora B-INCENP Ki < 0.001 µM) over Aurora-A Ki = 1.4 µM 
(28). In clinical studies, barasertib has been evaluated in patients 
with solid malignant tumors (30), advanced solid tumors (31), 
and hematologic cancers (32–35). The pharmacokinetic profiles 
of barasertib and barasertib-hQPA were investigated in a small 
phase I study in patients with newly diagnosed, relapsed or 
refractory acute myeloid leukemia AML (29), and in this study, 
one patient achieved a complete response. In a phase 1/2 study to 
investigate the safety, efficacy, and pharmacokinetics of barasertib 
in patients with advanced AML, barasertib was administered as a 
continuous 7-day infusion every 21 days and the MTD was estab-
lished as 1200 mg (32). In part B of this study, 32 patients were 
TABLe 1 | Aurora kinase inhibitors in clinical trials.
Compound Structure Aurora 
inhibition
Reference
R
O
P
OH
OH,
 
Barasertib 
(AZD1152) 
R = H, 
Barasertib-hQPA
Aurora-A 
Ki = 1.4 µM
(28–35)
Aurora-B Ki 
<0.001 µM; for 
barasertib-hQPA
Alisertib 
(MLN8237)
Aurora-A 
IC50 = 1.2 nM
(36–47)
Aurora-B 
IC50 = 396.5 nM
Danusertib 
(PHA-739358)
Aurora-A 
IC50 = 13 nM
(48–56)
Aurora-B 
IC50 = 79 nM
AT9283
 
Aurora-A: 52% 
inhibition at 3 nM
(57–64)
Aurora-B: 58% 
inhibition at 3 nM
PF-03814735 Aurora-A 
IC50 = 5 nM
(65, 66)
Aurora-B 
IC50 = 0.8 nM
AMG 900 Aurora-A 
IC50 = 5 nM
(67–70)
Aurora-B 
IC50 = 4 nM
FiGURe 2 | Aurora-A and Aurora-B inhibition induces mitotic 
aberrations. (A) Aurora-A inhibition induces temporarily a mitotic arrest, 
cells exit from mitosis with multipolar and monopolar spindle formation 
leading to apoptosis. (B) Aurora-B inhibition induces endoredublication, 
chromosome misalignments, and polyploidy.
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a randomized Phase II study (35). In this study, patients were 
randomized 2:1 to be administered either barasertib 1200 mg (as 
a 7-day continuous intravenous infusion) or LDAC 20 mg (sub-
cutaneously twice daily for 10 days) in 28-days cycles. A higher 
objective complete response rate was reported with barasertib 
treatment: 35.4% compared with 11.5% observed with the LDAC 
treatment. The median overall survival for patients who received 
the barasertib treatment was longer relative to that observed with 
the LDAC treatment (35). Barasertib had a more toxic safety pro-
file compared with that of LDAC treatment, the most commonly 
observed adverse events were stomatitis (71% in barasertib group 
versus 15% in LDAC group) and febrile neutropenia [67% in 
barasertib group versus 19% in LDAC group; (35)].
Alisertib (MLN8237)
Alisertib (MLN8237; Table  1) is a selective inhibitor of the 
Aurora-A kinase, with an IC50 against Aurora-A of 1.2 and 
396.5  nM against Aurora-B (36, 37). Alisertib has been exten-
sively characterized using in vitro and in vivo preclinical models. 
It displays antiproliferative activity in a wide range of human 
tumor cell lines including lung, prostate, ovarian, and lymphoma 
cells (36). In relation to pediatric cancers, MLN8237 was active 
against neuroblastoma and Ewing sarcoma cell lines and effica-
cious in neuroblastoma and acute lymphoblastic leukemia (ALL) 
treated with barasertib at 1200 mg. The most frequently observed 
grade ≥3 adverse events were febrile neutropenia and stomatitis/
mucosal inflammation (32). In this investigation, treatment with 
barasertib resulted in an overall hematologic response rate of 25% 
with a manageable toxicity profile (32). A phase I study to inves-
tigate the safety, pharmacokinetics, and efficacy of barasertib in 
advanced AML was also undertaken in Japanese patients (33). 
Patients received barasertib as a continuous 7-day i.v. infusion 
every 21 days with no dose-limiting toxicities reported at doses 
up to and including 1200 mg, a dose that had been established as 
the MTD in a study by Lowenberg et al. (32). Febrile neutropenia, 
neutropenia, leukopenia, and thrombocytopenia were reported 
as the most frequent grade ≥3 adverse events (33), and in this 
investigation, an overall hematologic response rate of 19% was in 
line to response rates observed by Lowenberg et al. (32).
The safety and tolerability of barasertib has also been assessed 
in combination with low-dose cytosine arabinoside (LDAC) in 
elderly patients with newly diagnosed AML, considered unfit for 
intensive induction chemotherapy (34). In this study, patients 
received barasertib (7-day continuous intravenous infusion from 
day 1 to 7) and LDAC 20 mg (subcutaneously twice daily from 
day 1 to 10) of 28-day treatment cycles. This combination showed 
acceptable tolerability at doses up to and including 1000  mg of 
barasertib, which was established as the MTD; the most common 
grade ≥3 adverse event was febrile neutropenia. In this investi-
gation, the combination of barasertib and LDAC resulted in an 
overall response rate of 45% (34).
The efficacy, safety and tolerability of barasertib versus 
LDAC in elderly patients with AML were also investigated in 
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xenograft models (38). In vitro, alisertib also disrupts the viability 
of AML cell lines and primary AML cells (39) and significantly 
increases the in vitro and in vivo efficacy of nilotinib (40).
Given its broad spectrum of activity in preclinical models, alis-
ertib has been evaluated in Phase I and II clinical trials in patients 
with advanced solid tumors (41–43), in children with refractory/
recurrent solid tumors (44) and in hematologic malignancies. 
In a Phase I study of MLN8237 in relapsed/refractory multiple 
myeloma, Non-Hodgkin lymphoma, and chronic lymphocytic 
leukemia, patients received alisertib orally as either powder-in-
capsule (PIC) or enteric-coated tablet (ECT) formulation (45). 
The most commonly reported grade ≥3 adverse events were 
neutropenia, thrombocytopenia, anemia, and leukopenia. In this 
study, partial responses were observed in 6 patients (13%), and 
13 patients (28%) had stable disease for 1.9–11 months (45). The 
recommended phase II dose of alisertib (ECT formulation) was 
50 mg twice daily for 7 days in 21-day cycles [i.e., a 7-day treat-
ment followed by a 14-day recovery period; (45)].
Alisertib was evaluated in a Phase II study in patients with 
relapsed and refractory aggressive B- and T-Cell Non-Hodgkin 
lymphomas, and in this investigation, alisertib was administered 
orally at 50 mg, twice daily for 7 days in 21-day cycles (46). The 
most frequently observed grade ≥3 adverse events were neutro-
penia, leukopenia, anemia, and thrombocytopenia. In this study, 
the overall response rate for all treated patients was 27% (46). In 
an exploratory Phase II study, alisertib was assessed in AML and 
myelodysplastic syndrome [MDS; (47)]. In this investigation, ali-
sertib was administered at 50 mg twice daily for 7 days in 21-day 
cycles and shown a modest single-agent antileukemic activity. 
In AML patients, a 17% overall response rate was observed with 
an additional seventeen patients (49%) having stable disease 
(47), but no responses were reported in MDS patients. The most 
commonly observed grade ≥3 adverse events were febrile neutro-
penia, anemia, thrombocytopenia, neutropenia, and fatigue (47).
Danusertib (PHA-739358)
Danusertib (PHA-739358, Table  1) is a potent inhibitor of all 
three Aurora kinase isoforms (Aurora-A IC50 = 13 nM, Aurora-B 
IC50 = 79 nM, Aurora-C IC50 = 61 nM) (48, 49). In addition to 
the Aurora kinases, PHA-739358 has inhibitory activity against 
a number of other kinases with relevance as anticancer targets 
such as ABL, RET, and TRK-A (48, 49). PHA-739358 inhibits 
both the wild-type and mutant ABL kinase isoforms with clinical 
relevance, in particular ABL (T315I) which is one of the most 
common mutations found in imatinib-resistant patients (50).
In the clinical setting, danusertib has been assessed in patients 
with advanced or metastatic solid tumors (51, 52). In these Phase 
I and II studies, danusertib was generally well tolerated, neutro-
penia being one of the most commonly observed hematologic 
toxicities, but showed only marginal antitumor activity in patients 
with common advanced solid tumors who had failed systemic 
therapy (52). In addition, danusertib showed only minimal 
efficacy when it was assessed in a randomized Phase II study in 
patients with metastatic castration-resistant prostate cancer after 
docetaxel failure (53). In another Phase I study, danusertib was 
administered as 24-h infusion every 14  days with and without 
granulocyte colony-stimulating factor (G-CSF) and assessed in 
patients with advanced solid tumors (54). PHA-739358 has also 
been investigated in hematologic malignancies, including a phase 
II study in patients with chronic myeloid leukemia (CML) relaps-
ing on imatinib or other targeted therapies (55). In this study, two 
complete hematologic responses were reported in patients that 
both carrying the T315I BCR–ABL mutation. Patients received 
danusertib by a once-weekly 6-h infusion, which was reportedly 
well tolerated (55). Danusertib was also assessed in phase I study 
in adult patients with accelerated or blastic phase CML and 
philadelphia chromosome-positive ALL resistant or intolerant to 
imatinib and/or other second generation ABL kinase inhibitors 
(56). In this investigation, danusertib was administered by 3-h 
IV infusion, daily for either 7 consecutive days in a 14-day cycle 
(schedule A) or 14 consecutive days in a 21-day cycle (schedule 
B). The most frequently reported grade 3–4 adverse events were 
anemia, diarrhea, and febrile neutropenia. Four (20%) of the 
twenty evaluable patients responded to treatment, all on schedule 
A treatment and carrying the T315I BCR-ABL mutation (56). 
Overall in this study, danusertib has shown an acceptable toxic-
ity profile and also promising activity in patients with advanced 
hematologic malignancies resistant to imatinib and/or other 
second generation ABL kinase inhibitors (56).
AT9283
AT9283 (Table 1) is a small-molecule multitargeted kinase inhibi-
tor with potent Aurora kinase activity [Aurora-A: 52% inhibition 
at 3 nM; Aurora-B: 58% inhibition at 3 nM; (57)]. Other kinases 
inhibited by AT9283, with relevance as anticancer targets include 
JAK2, FLT-3, and ABL(T315I) (57). AT9283 showed potent anti-
proliferative activity against imatinib-resistant BCR-ABL+ cells 
including those carrying the ABL(T315I) mutation (58). AT9283 
displayed potent inhibitory activity against a range of human 
solid tumor cell lines (59), and antiproliferative activity against a 
panel of human aggressive B-(non-Hodgkin lymphoma) B-NHL 
cell lines (60).
AT9283 was assessed in Phase I clinical trials in patients 
with advanced solid malignancies (61), advanced malignan-
cies [administered as a weekly 24-h infusion; (62)] and in 
children and adolescents with solid tumors (63). A Phase I and 
pharmacodynamic study of AT9283 in patients with relapsed/
refractory leukemia or myelofibrosis was also reported (64). In 
the initial part of this study, AT9283 was administered as a 72-h 
continuous infusion every 21 days; and in the second part of the 
investigation, infusion duration was increased sequentially (in 
24-h increments) to 96 and 120 h. The MTD for a 72-h infusion 
was established as 108  mg/m2/d, and dose-limiting toxicities 
included myocardial infarction, hypertension, cardiomyopathy, 
tumor lysis syndrome, and pneumonia (64). In approximately 
one-third of patients with relapsed/refractory AML, bone mar-
row blasts decreased by at least 38% after treatment. However, 
these reductions in blasts were transient and no objective 
responses were achieved (64).
PF-03814735
PF-03814735 (Table 1) is a potent, orally bioavailable inhibitor 
of both Aurora-A and Aurora-B kinases (Aurora-A IC50 = 5 nM, 
Aurora-B IC50 = 0.8 nM); and also inhibits several other kinases 
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(e.g., FLT3, JAK2, TrkB, RET, MST3) by ≥90% at a compound 
concentration of 100 nM (65). PF-03814735 exhibited antipro-
liferative activity against a range of human tumor cell lines such 
as HCT-116, HL-60, A549, and H125 (65). In a Phase I clinical 
study, PF-03814735 was assessed in patients with advanced solid 
tumors (66). PF-03814735 was administered orally, once daily, as 
a single agent dosing at days 1–5 or 1–10 of 21-day cycles. Dose 
limiting toxicities included febrile neutropenia and increased lev-
els of aspartate amino transferase. It was generally well tolerated 
with a clinically manageable adverse events profile but limited 
antitumor activity was reported with 19 patients achieving stable 
disease (66).
AMG 900
AMG 900 (Table 1) is an orally bioavailable, potent and selec-
tive pan-Aurora kinase inhibitor (67–70). It inhibits Aurora-A, 
-B, and -C with IC50 values of 5, 4, and 1 nM respectively, and 
in cells shows a phenotype consistent with Aurora-B inhibition 
(67). AMG 900 displayed potent antiproliferative activity against 
a range of human tumor cells including cells lines resistant to 
paclitaxel and the Aurora kinase inhibitors AZD1152, MK-0457, 
and PHA739358 (67). Notably, AMG 900 was consistently 
potent against tumor cells irrespective of P-gp or BCRP status 
(67). Consistent with the in vitro findings, AMG 900 inhibited 
the growth of multiple human tumor xenograft models [e.g., 
MDA-MB-231, HCT116, NCI-H460-PTX (MDR), MES-SA, 
MES-SA-Dx5 (MDR)] in  vivo, using either intermittent or 
continuous dosing schedules (67). The activity of AMG 900 as 
a single agent and in combination with paclitaxel or ixabepilone 
in multidrug-resistant TNBC (triple negative breast cancer) cell 
lines was also investigated (70). AMG 900 potently inhibited the 
growth of P-gp-expressing TNBC cell lines. In combination with 
paclitaxel or ixabepilone, AMG 900 enhanced the antiprolifera-
tive activity of these microtubule-targeting agents in TNBC cells 
in vitro and in human tumor xenograft models in vivo (70). AMG 
900 is currently being evaluated in Phase I clinical trials in adult 
patients with advanced solid and hematologic cancers (68).
Aurora Kinase inhibitors in Hematologic 
Malignancies
The most profound explanation for the limited response of the 
Aurora kinase inhibitor’s in solid tumors in a clinical setting 
is possibly the need for drug exposures through a number of 
cell cycles (for the Aurora-B and pan Aurora inhibitors) or for 
a prolonged time in mitosis (for the Aurora-A inhibitors), to 
induce their maximum effect in tumor cells before severe toxic 
effects such as neutropenia appear. The clinical evaluation of 
Aurora kinase inhibitors, as discussed earlier, indicated toxicities 
that are consistent with the mechanism of action for this class 
of compounds. In clinical setting, efficacy against solid tumors 
is limited, but overall, Aurora kinase inhibitors showed greater 
promise against hematologic malignancies. The observed sig-
nificant response in patients with hematologic cancers may be 
associated with their proliferation rate as well as with secondary 
pharmacology exhibited by some of these inhibitors which is 
related to the disease (Figure 3A).
AML is a heterogeneous class of leukemia, with prognosis 
predicted by a number of genetic and molecular abnormalities. 
Mutations of the fms-like tyrosine kinase 3 (FLT3) gene are one 
of the best characterized genetic alterations, which is frequently 
mutated in AML. These mutations can consist of internal tandem 
duplication (ITD) of the juxtamembrane domain coding region, 
or point mutations of the tyrosine kinase domain (TKD). Both 
FLT3-ITD and FLT3-TKD mutations result in ligand-independ-
ent proliferation and are associated with a poor prognosis in 
adults and children (71).
AZD1152 was the first selective Aurora-B inhibitor that was 
evaluated in pre-clinical and clinical studies. AZD1152 has 
demonstrated impressive efficacy in animal models using human 
tumor xenografts of AML cell lines with wild type and mutant 
FLT3 (72–74). Aurora-B inhibition was demonstrated, using 
phosphorylation of histone H3 (a known substrate of Aurora-B), as 
a biomarker for target engagement in vitro and in vivo. Polyploidy 
was the predominant phenotype associated with Aurora-B inhi-
bition due to cytokinesis failure and endoreduplication. It has 
been also shown that a secondary target of AZD1152 is FLT3, 
resulting in higher sensitivity of FLT3-mutated cell lines MV4-11 
and MOLM-13 to AZD1152 inhibition, compared to FLT3-WT 
cell lines (75). Based on these data, AZD1152 entered a number of 
clinical trials in patients with solid tumors or hematologic malig-
nancies, including AML, as described previously in this review.
Although FLT3 kinase has attracted a great interest in recent 
years as a target for AML treatment, the clinical impact of early 
FLT3 inhibitors has been limited when used as single agents, due 
to acquired resistance (76). Newer FLT3 inhibitors with improved 
selectivity, pharmacokinetic and pharmacodynamic properties 
may have improved single-agent efficacy (77), but clinical resist-
ance, including acquired secondary mutations in the FLT3-TKD, 
is emerging. However, FLT3 inhibitors exhibiting secondary 
kinase inhibition pharmacology showed promise in overcoming 
this resistance. For example, it was demonstrated that a human 
FLT3-ITD+ AML cell line harboring a secondary D835Y muta-
tion, has high relative resistance to the FLT3 inhibitors AC220, 
MLN518, and Sorafenib, but not to CCT137690, a dual FLT3-
Aurora kinase inhibitor (78). CCT241736, an advanced analog of 
CCT137690, is a preclinical development candidate for the treat-
ment of human malignancies, and in particular AML in adults 
and children (79). CCT241736 is an orally bioavailable dual 
FLT3/Aurora kinase inhibitor that also inhibits clinically relevant 
FLT3-resistant mutants including FLT3-ITD and FLT3 [D835Y; 
(79)]. CCT241736 significantly inhibited the growth of MV4-11 
human FLT3-ITD positive AML tumor xenografts in vivo, with 
biomarker modulation and free drug exposure consistent with 
dual FLT3 and Aurora kinase target inhibition (79).
Aurora inhibitors in Neuroblastoma
Neuroblastoma is the most common extra-cranial solid tumor 
of childhood, accounting for approximately 10% of pediatric 
tumors, which affects more than ten thousand children world-
wide each year. Stage 4 neuroblastoma represents approximately 
50% of cases with metastatic dissemination at diagnosis and its 
prognosis is poor. Therefore, novel therapeutic strategies are 
urgently needed to improve the prognosis of neuroblastoma 
FiGURe 3 | Schematic representation of Aurora inhibitor-targeted pathways. (A) Selective inhibition of Aurora-A or Aurora-B or dual specificity Aurora/FLT3 
compounds induces cytokinesis failure and inhibition of leukemic proliferation. (B) Conformational changes of Aurora-A by a compound induce Aurora-A-FBXW7-
MYCN complex disassembly and proteolytic degradation of MYCN. (C) Aurora-A is involved in DNA repair pathways and Aurora-A inhibitors confer increased 
cellular sensitivity to cell death.
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patients. Amplification of the MYCN gene is associated with an 
aggressive form of neuroblastoma that results in a particularly 
poor clinical outcome (80). Knockout of MYCN protein by 
targeting with siRNA, or alternatively, destabilizing the protein 
using an inhibitor of the upstream PI3K signaling pathway, has 
been shown as an effective preclinical therapy for neuroblas-
toma (81, 82).
Initially, a study using the pan Aurora inhibitor CCT137690 
showed that treatment of MYCN-amplified neuroblastoma cell 
lines inhibits cell proliferation and decreases MYCN protein 
expression (83). Importantly, in a transgenic mouse model of 
neuroblastoma (TH-MYCN) that overexpresses MYCN protein 
and is predisposed to spontaneous neuroblastoma formation, 
this compound significantly inhibits tumor growth (83). Later, 
an additional mechanistic study shown that Aurora-A forms 
a complex with MYCN in MYCN-amplified neuroblastoma 
cells, which protects MYCN from proteasomal degradation 
in mitosis (26). This activity was specific for Aurora-A, since 
neither Aurora-B inhibition nor depletion affected MYCN 
protein levels. Interestingly, stabilization of MYCN does not 
require the catalytic activity of Aurora-A (26). Furthermore, 
MYCN destabilization was not due to cell cycle arrest in G2/M 
due to inhibition of the catalytic activity of Aurora-A. However, 
crystallographic evidence showed that the Aurora-A-specific 
inhibitor MLN8054 (84) induces a DFG-up conformation, 
disrupting the Aurora-A/MYCN complex leading to MYCN 
degradation. The conclusions from this study were that disrup-
tion of the Aurora-A/MYCN complex promotes degradation of 
MYCN, mediated by the FBXW7 ubiquitin ligase. Therefore, 
inhibition of the Aurora kinases may be an effective strategy to 
treat MYCN-amplified neuroblastoma. In a completely different 
approach, a recent study provided evidence for an Aurora-A 
conformation-specific effect on proteolytic degradation of 
MYCN. CD532, an ATP-mimetic ligand, binds Aurora-A in a 
DFG-in, inactive conformation, which results in blocking both 
the kinase-dependent and independent functions of Aurora-A 
(27). Importantly, CD532 inhibits Aurora-A at low nanomolar 
concentrations and, in parallel, effects the proteolytic degrada-
tion of MYCN proposing an additional strategy to block MYCN 
in cancer (Figure 3B).
Aurora inhibitors and DNA Damage
A great effort has been focused on investigating different 
approaches to enhance the effect of Aurora kinase inhibitors 
in preclinical models and in clinical trials, including investigat-
ing the role of Aurora-A in DNA-damage response (DDR). It 
is known that Aurora-A activity is tightly regulated during the 
response to genotoxic agents and is important for a normal DDR 
(85, 86). There is an intricate connection between the DDR and 
the cell cycle at multiple levels. Once the homologous recombi-
nation (HR) machinery is fully active, the cell cycle is normally 
stalled by the activation of the DNA damage checkpoints. 
For the G2/M DNA damage checkpoint, the cell cycle arrest 
is mostly achieved by the regulation of CDC25 phosphatases 
and WEE1, either by the checkpoint kinases CHK1 and CHK2, 
or by the ATM/ATR kinases-dependent phosphorylation of 
December 2015 | Volume 5 | Article 2787
Bavetsias and Linardopoulos Aurora Kinase Inhibitors in the Clinic
Frontiers in Oncology | www.frontiersin.org
PLK1 (Figure 3C). These two pathways converge to maintain 
an efficient inhibition of CDK1 and hence prevent cell cycle 
progression. Finally, during recovery from the DNA damage 
checkpoint, the signal emanating from the mitotic kinase 
PLK1 becomes dominant and stimulates cell cycle progression. 
Interestingly, during this late phase of the DDR, but also during 
unperturbed cell cycle, Aurora-A has been identified as the 
upstream activator of PLK1 (87, 88).
A recent study has shown that Aurora-A modulates the repair 
of DNA double-strand breaks [DSBs; (89)]. Aurora-A expression 
inhibits RAD51 recruitment to DNA DSBs, decreases DSB repair 
by HR and sensitizes cancer cells to PARP inhibition (89). This 
impairment of RAD51 function requires inhibition of CHK1 
by PLK1. These results identify a novel function of Aurora-A in 
modulating the response to DNA DSB that likely contributes to 
carcinogenesis and suggest a novel therapeutic approach to the 
treatment of cancers overexpressing this protein. The connection 
of DDR with Aurora kinases triggered a number of trials combin-
ing radiotherapy with Aurora kinase inhibitors. AZD1152, the 
Aurora-B kinase inhibitor, was shown to enhance the effect of 
ionizing radiation (IR) in three different settings: neoadjuvant 
(AZD1152 before IR), adjuvant (IR before AZD1152), or con-
comitant treatments [AZD1152 plus one single IR dose; (90)]. 
A more pronounced tumor growth delay was observed in the 
neoadjuvant and adjuvant schedules as compared to the con-
comitant schedule. However, AZD1152 enhanced the efficacy 
of IR when concomitant IR was fractionated over several days. 
Histopathological examination revealed that AZD1152  +  IR 
induced polyploidy, multinucleation, and micronuclei in  vivo. 
Caspase inhibition or removal of the pro-apoptotic protein BAX 
did not ameliorate the long-term cell survival of AZD1152-
treated cancer cells. In contrast, a chemical inhibitor of CHK1, 
CHIR124, sensitized cancer cells to the lethal effect of AZD1152, 
supporting the contention that AZD1152 mediates radiosen-
sitization in  vivo by enhancing mitotic catastrophe (90). More 
recent studies using the Aurora-A selective inhibitor MLN8237 
showed the effect of MLN8237 with and without temozolomide 
or IR, on the proliferation of glioblastoma tumor stem-like 
cells. It was reported that Aurora-A inhibition by MLN8237 
was synergistic with temozolomide and potentiated the effects 
of IR on colony formation in neurosphere glioblastoma tumor 
stem-like cells, supporting the potential of Aurora-A inhibitors 
as primary chemotherapy agents or biologic response modifiers 
in glioblastoma patients (91).
CONCLUSiON AND FUTURe DiReCTiONS
Aurora kinase inhibitors were initially aimed to target solid 
tumors including ovarian, breast, lung and colon. Despite the 
wide use of different chemical classes of Aurora kinase inhibi-
tors in clinical trials, a limited efficacy against solid tumors was 
observed. The most plausible explanation for this result may 
relate to the proliferation rate of cells in solid tumors being rela-
tively slow. By the time that an Aurora kinase inhibitor had an 
effect through several cell cycles and mitoses in tumors, the faster 
proliferating bone marrow cells were severely affected. A break in 
treatment, to allow the patient to recover, enabled the tumors to 
continue growing. Regarding compound preclinical evaluation, it 
appears that for cell cycle inhibitors, particularly selective mitotic 
inhibitors, the existing pre-clinical efficacy models in which these 
compounds were evaluated are not predictive of the efficacy 
outcome in clinical trials. The disappointing outcome against 
solid tumors in the clinical setting led to a change in strategy 
with Aurora kinase inhibitors being evaluated in clinical trials 
against hematologic malignancies due to their higher homogene-
ity and higher proliferation rates relative to solid tumors. Higher 
response rates against hematologic malignancies were observed, 
in particular when the Aurora inhibitor exhibited a secondary 
anticancer pharmacology; for example, the inhibition of another 
oncogenic driver of hematologic cancers such as activated FLT3 
in AML. In conclusion, simultaneous inhibition of an activated 
oncogene driver and Aurora kinases using compounds with dual 
pharmacology or selective Aurora inhibitors in combination with 
a selective oncogene driver inhibitor may be a strategy to achieve 
a significantly improved clinical outcome, and also overcome 
resistance.
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